Search
muraglitazar (Pargluva)
Indications: diabetes mellitus type 2
Dosage: 5 mg PO QD
Adverse effects:
1) may be more likely than thiazolidinediones to cause edema & heart failure
2) increased mortality, risk of myocardial infarction, stroke (composite risk statisically significant) [3]
Mechanism of action:
1) glitazar, a so-called 2 in 1 drug
a) improves blood glucose similar to thiazolidinediones
b) improves lipid profile similar to fibrates
- lowers triglycerides almost 30%
- raises HDL almost 20%
2) activates both PPAR-alpha & PPAR-gamma
a) activation of PPAR-gamma decreases plasma glucose & free fatty acid concentrations
b) activation of PPAR-alpha receptors decreases plasma triglyceride & increases plasma HDL cholesterol
Interactions
drug interactions
drug adverse effects of hypoglycemic agents
General
glitazar
Database Correlations
PUBCHEM cid=206044
References
- Prescriber's Letter 12(9): 2005
Diabetes Drugs on the Horizon: Investigational Drug:
Muraglitazar (Pargluva)
Detail-Document#: 210905
(subscription needed) http://www.prescribersletter.com
- Internal Medicine News 38(16) August 2005
- Nissen SE, Wolski K, Topol EJ.
Effect of Muraglitazar on Death and Major Adverse
Cardiovascular Events in Patients With Type 2 Diabetes Mellitus.
JAMA. 2005 Oct 20; [Epub ahead of print]; JAMA 294(20):2581, 2005
PMID: 16239637
- Brophy JM, Selling safety - Lessons from muraglitazar
JAMA 294:2633, 2005
PMID: 16239638